Citi analyst Yigal Nochomovitz downgrades $Summit Therapeutics (SMMT.US)$ to a hold rating, and adjusts the target price from $19 to $23.
According to TipRanks data, the analyst has a success rate of 45.9% and a total average return of 14.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Summit Therapeutics (SMMT.US)$'s main analysts recently are as follows:
Since May, following significant share price appreciation, Summit Therapeutics has exceeded prior market expectations. The company's value has surged with a market capitalization reaching $16B, propelled by optimistic results from the HARMONi-2 study. While acknowledging the potential for shares to rise swiftly with further positive outcomes from HARMONi-2/3/6 studies or pivotal data in areas other than lung cancer, visibility on the timing remains low. The current valuation is perceived as reasonable for the time being.
Investor focus is appropriately centered on the outcomes from the HARMONi-2 study, which compares ivonescimab directly with pembrolizumab. Nonetheless, a range of significant data presentations at WCLC24 and ESMO24 concerning the PD-[L]1/VEGF class for various solid tumor types deserves attention. The array of data presented at ESMO24 has led to an increase in the perceived likelihood of success for all indications within this class.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析师Yigal Nochomovitz下调$Summit Therapeutics (SMMT.US)$至持有评级，并将目标价从19美元上调至23美元。
根据TipRanks数据显示，该分析师近一年总胜率为45.9%，总平均回报率为14.1%。
此外，综合报道，$Summit Therapeutics (SMMT.US)$近期主要分析师观点如下：
自5月以来，在股价大幅上涨之后，Summit Therapeutics已经超出了先前的市场预期。在Harmoni-2研究的乐观结果的推动下，该公司的价值激增，市值达到160亿美元。尽管承认随着Harmoni-2/3/6研究的进一步积极结果或肺癌以外领域的关键数据，股价有可能迅速上涨，但对时机的知名度仍然很低。目前的估值目前被认为是合理的。
投资者的注意力恰当地集中在Harmoni-2研究的结果上，该研究直接将依文西单抗与pembrolizumab进行了比较。尽管如此，WCLC24 和 ESMO24 上公布的有关各种实体瘤类型的 PD-[L] 1/VEGF 类别的一系列重要数据值得关注。ESMO24 上提供的一系列数据使该类别中所有适应症的成功可能性增加。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
